- CA$29.26m
- CA$121.11m
Brief: Eastern Capital Ltd acquires additional shares and warrants of Resverlogix Corp
Brief: Resverlogix closed offering, issuing a total of $10 million of equity units
Brief: RESVERLOGIX TO RAISE UP TO $10 MILLION
Brief: Resverlogix announces third positive recommendation from data safety monitoring board for Apabetalone
Brief: Resverlogix announces receipt of notice of allowance from the U.S. Patent And Trademark Office
Brief: Resverlogix says proposed Phase 2A kidney dialysis study design to be separated in two parts
Brief: Resverlogix provides groundbreaking results in patients with severe kidney impairments
Brief: Resverlogix announces second positive recommendation for Apabetalone (RVX-208) Phase 3 study
Brief: Resverlogix says announces successful phase 1 renal trial results
Brief: Resverlogix announces positive recommendation from data safety monitoring board for Apabetalone phase 3 study
Brief: Resverlogix updates On Apabetalone (RVX-208) study
Brief: Resverlogix Corp announces dosing of first two patients in expanded renal and orphan programs
Brief: Resverlogix explores potential of Apabetalone in phase 3 Betonmace clinical study
Brief: Resverlogix strengthens board, appoints new chairman
Brief: Resverlogix commences phase 3 clinical trial BETonMACE with Apabetalone
CANADA RESEARCH ROUNDUP: Blackberry, BCE, Cineplex, Quebecor
CANADA RESEARCH ROUNDUP: Blackberry, BCE, Cineplex, Quebecor